PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism

Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells

(2021) Yu-xiang Wang et al.   Cell Death & Disease

Integrating immunotherapy and targeted therapy in cancer treatment: Mechanistic insights and clinical implications

(2020) Johann S. Bergholz et al.   CLINICAL CANCER RESEARCH

Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity

(2020) Pu Sun et al.   ACTA PHARMACOLOGICA SINICA

Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors

(2020) Hao-Yue Xiang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment

(2020) Vitaliy Davidov et al.   Frontiers in Immunology

Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity

(2020) Alison E. Ringel et al.   CELL

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors

(2019) Ariella B. Hanker et al.   Cancer Discovery

The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function

(2019) Stalin Chellappa et al.   JOURNAL OF IMMUNOLOGY

PI 3K δ is a Treg target in cancer immunotherapy

(2019) Ee Lyn Lim et al.   IMMUNOLOGY

Comprehensive Integration of Single-Cell Data

(2019) Tim Stuart et al.   CELL

Alpelisib: First Global Approval

(2019) Anthony Markham   DRUGS

Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer

(2019) Nithya Sivaram et al.   JOURNAL OF CLINICAL INVESTIGATION

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

(2019) Ali S. Alzahrani   SEMINARS IN CANCER BIOLOGY

PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment

(2019) Jia-jie Shi et al.   CANCER LETTERS

For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors

(2019) Buchanan et al.   Biomolecules

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer

(2018) Xue-ling Liu et al.   CANCER LETTERS

The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations

(2018) Dearbhaile C. Collins et al.   CURRENT CANCER DRUG TARGETS

FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity

(2018) Theresa L. Whiteside   EXPERT OPINION ON THERAPEUTIC TARGETS

Fatty acid synthase (FASN) as a therapeutic target in breast cancer

(2017) Javier A. Menendez et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses

(2016) Jiqing Sai et al.   CLINICAL CANCER RESEARCH

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences

(2016) Kui Yang et al.   TRENDS IN BIOCHEMICAL SCIENCES

Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer

(2016) Yujun Hao et al.   Nature Communications

Macrophage PI3K  Drives Pancreatic Ductal Adenocarcinoma Progression

(2016) M. M. Kaneda et al.   Cancer Discovery

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

(2015) Q. Yang et al.   CLINICAL CANCER RESEARCH

Short communication: Effect of inhibition of fatty acid synthase on triglyceride accumulation and effect on lipid metabolism genes in goat mammary epithelial cells

(2015) J.J. Zhu et al.   JOURNAL OF DAIRY SCIENCE

What is synergy? The Saariselkä agreement revisited

(2015) Jing Tang et al.   Frontiers in Pharmacology

Genetic Analysis of the Role of the PI3K-Akt Pathway in Lipopolysaccharide-Induced Cytokine and Tissue Factor Gene Expression in Monocytes/Macrophages

(2014) J. P. Luyendyk et al.   JOURNAL OF IMMUNOLOGY

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

(2014) Khaled Ali et al.   NATURE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway

(2014) R. Abu-Eid et al.   Cancer Immunology Research

GSVA: gene set variation analysis for microarray and RNA-Seq data

(2013) Sonja Hänzelmann et al.   BMC BIOINFORMATICS

Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer

(2013) Xian Li et al.   CANCER LETTERS

Macrophage-Derived AIM Is Endocytosed into Adipocytes and Decreases Lipid Droplets via Inhibition of Fatty Acid Synthase Activity

(2010) Jun Kurokawa et al.   Cell Metabolism